Literature DB >> 31634983

Profiles of advanced hepatic fibrosis evaluated by FIB-4 index and shear wave elastography in health checkup examinees.

Sakura Yamamura1, Takumi Kawaguchi1, Dan Nakano1, Yoshiko Tomiyasu2, Shinobu Yoshinaga2, Yumi Doi2, Hirokazu Takahashi3, Keizo Anzai3, Yuichiro Eguchi3,4, Takuji Torimura1, Naoto Shiba5.   

Abstract

AIM: Advanced hepatic fibrosis is seen in individuals with potential hepatocellular carcinoma and cardiovascular disease. Hepatic fibrosis can be assessed using a combination of the FIB-4 index and imaging modalities, including shear wave elastography. We aimed to investigate the prevalence of advanced fibrosis in the general population and the profiles associated with advanced fibrosis using a data-mining analysis.
METHODS: We enrolled 1155 health checkup examinees (median age 53 years, 685 women, 470 male). Advanced fibrosis was defined by FIB-4 index ≥1.3 and liver stiffness ≥8.07 kPa using shear wave elastography. Participants were classified as normal-mild fibrosis (n = 1035) or advanced fibrosis (n = 120). Factors associated with advanced fibrosis were analyzed by logistic regression and decision-tree analyses.
RESULTS: Advanced fibrosis was observed in 10.4% of participants (120/1155). In the logistic regression analysis, independent factors for advanced fibrosis were age (≥75 years; OR 2.12, 95% CI 1.021-4.415; P = 0.0419) and the presence of metabolic syndrome (OR 2.51, 95% CI 1.416-4.462; P = 0.0017). The decision-tree analysis showed two profiles associated with advanced fibrosis: profile 1 - individuals aged ≥65 years with metabolic syndrome and mild-to-moderate alcohol consumption (prevalence of advanced fibrosis 73.3%); and profile 2 - individuals without metabolic syndrome, aged ≥75 years, with no exercise habit (prevalence of advanced fibrosis 56.3%).
CONCLUSIONS: Advanced fibrosis was observed in 10.4% of health checkup examinees. Furthermore, we showed that aging, metabolic syndrome with mild-to-moderate alcohol consumption, and physical inactivity were associated with advanced fibrosis. Thus, prevention of metabolic syndrome and alcohol withdrawal, as well as exercise habits, might inhibit the progression of hepatic fibrosis.
© 2019 The Japan Society of Hepatology.

Entities:  

Keywords:  2-D shear wave elastography; data-mining analysis; lifestyle; liver stiffness; non-invasive test algorithm

Year:  2019        PMID: 31634983     DOI: 10.1111/hepr.13436

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  8 in total

1.  Application value and feasibility analysis of humanistic health management for cancer screening in physical examination.

Authors:  Lijin Yan; Zhiqi Huang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 2.  Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis.

Authors:  Takashi Yamaguchi; Katsunori Yoshida; Miki Murata; Kanehiko Suwa; Koichi Tsuneyama; Koichi Matsuzaki; Makoto Naganuma
Journal:  Int J Mol Sci       Date:  2022-06-03       Impact factor: 6.208

3.  Interaction of metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019.

Authors:  Martín Uriel Vázquez-Medina; Eira Cerda-Reyes; Alberto Galeana-Pavón; Carlos Enrique López-Luna; Patty Marlen Ramírez-Portillo; Gabriela Ibañez-Cervantes; Julián Torres-Vázquez; Cruz Vargas-De-León
Journal:  Hepatol Commun       Date:  2022-04-19

4.  Profiles Combining Muscle Atrophy and Neutrophil-to-Lymphocyte Ratio Are Associated with Prognosis of Patients with Stage IV Gastric Cancer.

Authors:  Kota Shigeto; Takumi Kawaguchi; Shunji Koya; Keisuke Hirota; Toshimitsu Tanaka; Sachiko Nagasu; Masaru Fukahori; Tomoyuki Ushijima; Hiroo Matsuse; Keisuke Miwa; Koji Nagafuji; Takuji Torimura
Journal:  Nutrients       Date:  2020-06-24       Impact factor: 5.717

5.  Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis.

Authors:  Kanehiko Suwa; Takashi Yamaguchi; Katsunori Yoshida; Miki Murata; Mayuko Ichimura; Koichi Tsuneyama; Toshihito Seki; Kazuichi Okazaki
Journal:  Cancers (Basel)       Date:  2020-01-24       Impact factor: 6.639

Review 6.  MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Authors:  Takumi Kawaguchi; Tsubasa Tsutsumi; Dan Nakano; Mohammed Eslam; Jacob George; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2021-11-10

7.  MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men.

Authors:  Tsubasa Tsutsumi; Dan Nakano; Machiko Kawaguchi; Ryuki Hashida; Shinobu Yoshinaga; Hirokazu Takahashi; Keizo Anzai; Takumi Kawaguchi
Journal:  Diabetol Metab Syndr       Date:  2022-08-16       Impact factor: 5.395

8.  Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study.

Authors:  Shuhei Fukunaga; Dan Nakano; Takumi Kawaguchi; Mohammed Eslam; Akihiro Ouchi; Tsutomu Nagata; Hidefumi Kuroki; Hidemichi Kawata; Hirohiko Abe; Ryuichi Nouno; Koutaro Kawaguchi; Jacob George; Keiichi Mitsuyama; Takuji Torimura
Journal:  Int J Mol Sci       Date:  2021-05-22       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.